Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Paul B. Chapman; Axel Hauschild; Caroline Robert; John B.A.G. Haanen; Paolo A. Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Célèste Lebbé; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven O’Day; Jeffrey A. Sosman; John M. Kirkwood; Alexander M.M. Eggermont; Brigitte Dréno; K. B. Nolop; Jiang Li; B. Nelson; Jeannie Hou; Richard J. Lee; Keith T. Flaherty; Grant A. McArthur

doi:10.1056/nejmoa1103782

Key Points

The aim is to evaluate the effectiveness of vemurafenib in improving survival rates for melanoma patients with the BRAF V600E mutation.
Randomized trial design
Evaluated patients with untreated melanoma and BRAF V600E mutation
ClinicalTrials.gov number NCT01006980
Improved overall survival rates reported in patients treated with vemurafenib, with statistical significance (exact metrics not provided)
Progression-free survival rates also improved, indicating beneficial effects of the drug.

Implication

Randomized trial shows improved survival rates in melanoma with BRAF V600E mutation using vemurafenib, indicating a significant treatment advancement.

Abstract

Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation. (Funded by Hoffmann-La Roche; BRIM-3 ClinicalTrials.gov number, NCT01006980.).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chapman et al. (2011) studied this question.

synapsesocial.com/papers/69d7370bf07a12db70b8a5b5 https://doi.org/10.1056/nejmoa1103782

View Full Paper

Ask AI

Bookmark

Share

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Key Points

Implication

Abstract

Discussion

Cite This Study

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading